NCT03912805View on ClinicalTrials.gov

ET-01 in Subjects With Lateral Canthal Lines, LCL-209

PHASE2CompletedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

February 27, 2019

Primary Completion Date

May 6, 2019

Study Completion Date

October 4, 2019

Conditions
Lateral Canthal Lines, LCLCrow's Feet
Interventions
BIOLOGICAL

botulinum toxin, Type A

topical liniment

BIOLOGICAL

Vehicle

Vehicle Formulation

Trial Locations (3)

19067

Yardley Dermatology Associates, Yardley

23502

Virginia Clinical Research, Inc., Norfolk

33781

Synexis, Inc., Pinellas Park

Sponsors
All Listed Sponsors
lead

Eirion Therapeutics Inc.

INDUSTRY